Drugs / RVM-V001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05420077 | Sep 2022 → Jun 2023 | COVID-19 | RVAC Medicines (US), Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05788185 | Mar → Sep 2023 | COVID-19 | RVAC Medicines (US), Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RVM-V001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05420077 ↗ |
| Modality | Vaccine | “study vaccine” NCT05420077 ↗ |
| Route | Intramuscular | “intramuscular (IM) injection” NCT05420077 ↗ |